DaVita physicians are expected to begin treating patients with Vafseo (vadadustat) in August 2025 as part of an operational pilot program. This initiative aims to introduce a new therapy for anemia due to chronic kidney disease in adults receiving dialysis.
The pilot program will be implemented across more than 100 DaVita dialysis clinics. This significant scale suggests a strategic move to evaluate the drug's efficacy and operational integration within DaVita's extensive network.
Akebia Therapeutics, the developer of Vafseo, anticipates that this pilot will lead to broad prescribing of the drug across DaVita's facilities before the end of the year. This represents a potential for improved patient care and a new treatment option for DaVita's patient population.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.